1970Proceedings of Anticancer ResearchOpen access

Diagnostic Value of CYFRA21-1, CA19-9 and SCCAg Detection in Esophageal Cancer

Chunran Du, Yanming Wang, Shenyan Hou

Open full text 0 citations

Abstract

Objectives To investigate the value of serum cytokeratin 19 fragment (CYFRA21-1), carbohydrate anti-gen 19-9 (CA19-9) and squamous cell carcinoma antigen (SCCAg) in the diagnosis of esophageal cancer. Methods 100 cases of esophageal cancer (study group) and 50 healthy subjects (control group) were recruited in the study, the serum levels of CYFRA21-1, CA19-9 and SCCAg in these patients were detected. Subgroups analysis was performed in study group by clinical staging, and the diagnostic value of CYFRA21-1, CA19-9 and SCCAg in detecting esophageal cancer was analyzed by receiver operating characteristic curve (ROC). Results The serum levels of CYFRA21-1, CA19-9 and SCCAg in study group were significantly higher than those in control group, and those were significantly lower in patients with stageⅠ-Ⅱ disease than those with stage Ⅲ and Ⅳ disease, indicating statistically significant difference (P<0.01); the sensitivity of serum CYFRA21-1, CA19-9 and SCCAg in the diagnosis of esophageal cancer was 82.26%, and specificity was 91.33%, with positive predictive value being 86.14%, and negative predictive value being 89.57%, and AUC value was 0.864, the combined detection was superior to each measure utilized alone, the difference was significantly significant (P<0.05). Conclusion The combined detection of serum CYFRA21-1, CA19-9, and SCCAg can significantly improve the diagnostic sensitivity and specificity in detecting the esophageal cancer.

Open-access reader

About this research paper

What this paper is about

Objectives To investigate the value of serum cytokeratin 19 fragment (CYFRA21-1), carbohydrate anti-gen 19-9 (CA19-9) and squamous cell carcinoma antigen (SCCAg) in the diagnosis of esophageal cancer. Methods 100 cases of esophageal cancer (study group) and 50 healthy subjects (control group) were recruited in the study, the serum levels of CYFRA21-1, CA19-9 and SCCAg in these patients were detected. Subgroups analysis was performed in study group by clinical staging, and the diagnostic value of CYFRA21-1, CA19-9 and SCCAg in detecting esophageal cancer was analyzed by receiver operating characteristic curve (ROC). Results The serum levels of CYFRA21-1, CA19-9 and SCCAg in study group were significantly higher than those in control group, and those were significantly lower in patients with stageⅠ-Ⅱ disease than those with stage Ⅲ and Ⅳ disease, indicating statistically significant difference (P<0.01); the sensitivity of serum CYFRA21-1, CA19-9 and SCCAg in the diagnosis of esophageal cancer was 82.26%, and specificity was 91.33%, with positive predictive value being 86.14%, and negative predictive value being 89.57%, and AUC value was 0.864, the combined detection was superior to each measure utilized alone, the difference was significantly significant (P<0.05). Conclusion The combined detection of serum CYFRA21-1, CA19-9, and SCCAg can significantly improve the diagnostic sensitivity and specificity in detecting the esophageal cancer.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objectives To investigate the value of serum cytokeratin 19 fragment (CYFRA21-1), carbohydrate anti-gen 19-9 (CA19-9) and squamous cell carcinoma antigen (SCCAg) in the diagnosis of esophageal cancer. Methods 100 cases of esophageal cancer (study group) and 50 healthy subjects (control group) were recruited in the study, the serum levels of CYFRA21-1, CA19-9 and SCCAg in these patients were detected. Subgroups analysis was performed in study group by clinical staging, and the diagnostic value of CYFRA21-1, CA19-9 and SCCAg in detecting esophageal cancer was analyzed by receiver operating characteristic curve (ROC). Results The serum levels of CYFRA21-1, CA19-9 and SCCAg in study group were significantly higher than those in control group, and those were significantly lower in patients with stageⅠ-Ⅱ disease than those with stage Ⅲ and Ⅳ disease, indicating statistically significant difference (P<0.01); the sensitivity of serum CYFRA21-1, CA19-9 and SCCAg in the diagnosis of esophageal cancer was 82.26%, and specificity was 91.33%, with positive predictive value being 86.14%, and negative predictive value being 89.57%, and AUC value was 0.864, the combined detection was superior to each measure utilized alone, the difference was significantly significant (P<0.05). Conclusion The combined detection of serum CYFRA21-1, CA19-9, and SCCAg can significantly improve the diagnostic sensitivity and specificity in detecting the esophageal cancer.

Key concepts: Medicine, Internal medicine, Esophageal cancer, Receiver operating characteristic, CA19-9, Gastroenterology, Stage (stratigraphy), Esophageal squamous cell carcinoma

Related papers

Back to paper searchBrowse research topicsOriginal source
Diagnostic Value of CYFRA21-1, CA19-9 and SCCAg Detection in Esophageal Cancer — Research Paper | ScholarLens